Literature DB >> 19399327

[Refractory dermatomyositis associated with chronic organizing pneumonia treated with rituximab: report of one case].

Jorge Yáñez V1, Marcela Cisternas M, Velia Saldías H, Fernando Saldías P.   

Abstract

Chronic organizing pneumonia (COP) has often been reported as a pulmonary manifestation of collagen vascular diseases, mainly rheumatoid arthritis, but the association of COP and dermatomyositis (DM) has rarely been documented. We report a 55 year-old woman with well-documented DM and a COP. She was refractory to steroids and two other immunosuppressive agents therapy (cyclophosphamide and azathioprine). Therefore, rituximab (2 x 1 g infusions) was used for treatment. During the following weeks her strength gradually increased while creatine kinase (CK), C reactive protein and erythrocyte sedimentation rate normalized. After 6 months, she had a relapse with increased muscle enzymes, fever and moderate muscle weakness. After a second course of rituximab (2 x 1 g infusions), the patient demonstrated a remarkable clinical response as indicated by an increase in muscle strength and moderate decline in creatine kinase levels. Lung abnormalities resolved significantly on high resolution chest CT scan. Thus, B-cell depletion therapy with rituximab used alone or in combination with other immunosuppressants may be a viable option in patients with polymyositis-dermatomyositis and pneumonia refractory to current therapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19399327     DOI: /S0034-98872009000100013

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  2 in total

Review 1.  Bronchiolitis obliterans organizing pneumonia in patients with autoimmune rheumatic diseases.

Authors:  Carmen Maria Lara Rojas; Elisabetta Borella; Lavinia Palma; Silvio Ragozzino; Enrique De Ramón; Ricardo Gomez-Huelgas; Leonardo Punzi; Andrea Doria
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

Review 2.  Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature.

Authors:  Linda Nalotto; Luca Iaccarino; Margherita Zen; Mariele Gatto; Elisabetta Borella; Marta Domenighetti; Leonardo Punzi; Andrea Doria
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.